This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

This study has been completed.
Department of Health and Human Services
Information provided by (Responsible Party):
Novavax Identifier:
First received: November 17, 2014
Last updated: September 20, 2016
Last verified: September 2016
The purpose of this study is to determine the immune response of three dose levels of the Quadrivalent VLP vaccine in healthy young (18-49) adults. The study is broken down into four treatment groups. Each group will enroll 100 subjects, for a total of 400 subjects. Groups A-C will receive one of three dose levels of the Quadrivalent VLP vaccine, and Group D will receive a commercially available trivalent influenza vaccine (TIV). The study will also evaluate the safety and tolerability of the Quadrivalent VLP vaccine formulations.

Condition Intervention Phase
Influenza Biological: Quadrivalent VLP Vaccine Biological: Comparator TIV Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults

Resource links provided by NLM:

Further study details as provided by Novavax:

Primary Outcome Measures:
  • Immunogenicity of the quadrivalent VLP vaccine using HAI responses. [ Time Frame: Up to 6 months ]

    Derived/calculated endpoints based on:

    Seroconversion rate (SCR) Seroprotection rate (SPR) Geometric mean titer (GMT) Geometric mean ratio (GMR)

  • Safety of three quadrivalent VLP vaccine formulations. adverse events, Medically Attended Events (MAEs), Serious Adverse Events (SAEs), and Significant New medical Conditions (SNMCs) [ Time Frame: Up to 6 months ]
    Number and percentage of subjects with solicited local and systemic adverse events over the seven days post-injections; all adverse events (including adverse changes in clinical laboratory parameters) over 21 days post-injections; and Medically Attended Events (MAEs), Serious Adverse Events (SAEs), and Significant New medical Conditions (SNMCs) through six months.

Secondary Outcome Measures:
  • Immunogenicity of each quadrivalent VLP vaccine formulation measured by neuraminidase inhibition (NAI) [ Time Frame: Up to 6 months ]

    Derived/calculated endpoints based on:

    Two fold and four fold increases in NAI titer Geometric mean titer (GMT) Geometric mean ratio (GMR)

Enrollment: 400
Study Start Date: November 2014
Study Completion Date: June 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
Biological: Quadrivalent VLP Vaccine
Experimental: Group B
Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
Biological: Quadrivalent VLP Vaccine
Experimental: Group C
Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
Biological: Quadrivalent VLP Vaccine
Active Comparator: Group D
Comparator TIV, intramuscular injection (0.5mL)
Biological: Comparator TIV


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy adult male or female, 18-49 years of age
  2. Willing and able to give informed consent prior to study enrollment
  3. Able to comply with study requirements
  4. Women of child-bearing potential must have a negative urine pregnancy test at vaccination, will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of continuous abstinence from heterosexual activity, or prior surgical sterilization, hormonal contraceptives (oral, injectable, implant, patch, ring), barrier contraceptives (condom or diaphragm), and intrauterine device (IUD). Women with an adequately documented history of surgical sterility are exempt from urine pregnancy testing.

Exclusion Criteria:

  1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.

    • Asymptomatic conditions or findings (e.g., mild hypertension, dyslipidemia) that are not associated with evidence of end-organ damage are not exclusionary provided that they are being appropriately managed and are clinically stable (i.e., unlikely to result in symptomatic illness within the time-course of this study) in the opinion of the investigator.
    • Acute or chronic illnesses or conditions which may be reasonably predicted to become symptomatic if treatment were withdrawn or interrupted are exclusionary, even if stable.
    • Acute or chronic illnesses reasonably expected to be associated with increased risks associated with influenza (e.g., cardio-pulmonary diseases, diabetes mellitus, renal or hepatic dysfunction, hemoglobinopathies) are exclusionary, even if stable.
    • Note that illnesses or conditions may be exclusionary, even if otherwise stable, due to therapies used to treat them (see exclusion criteria 2,5,8,9).
  2. Participation in research involving investigational product (drug/ biologic/ device) within 45 days before planned date of first vaccination
  3. History of a serious reaction to prior influenza vaccination, known allergy to constituents of licensed TIV (e.g., egg proteins) or polysorbate-80.
  4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.
  5. Received any vaccine in the 4 weeks preceding the study vaccination and any influenza vaccine within six months preceding the study vaccination.
  6. History of receipt of any avian influenza vaccine containing an H5 antigen, or known exposure to birds infected with an H5 virus.
  7. Any known or suspected immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination.
  8. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose greater or equal to 10mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
  9. Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or during the study.
  10. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration.
  11. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  12. Known disturbance of coagulation.
  13. Women who are breastfeeding or plan to become pregnant during the study.
  14. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02307851

United States, California
Anaheim Clinical Trials
Anaheim, California, United States, 92801
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33143
United States, Kansas
Johnson County Clin Trials
Lenexa, Kansas, United States, 66219
United States, Nebraska
Meridian Clinical Research
Omaha, Nebraska, United States, 68134
United States, Texas
Clinical Trials of Texas
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Department of Health and Human Services
Study Director: D Nigel Thomas, Ph.D. Novavax
  More Information

Additional Information:
Responsible Party: Novavax Identifier: NCT02307851     History of Changes
Other Study ID Numbers: FLU-SIQ-206
Study First Received: November 17, 2014
Last Updated: September 20, 2016

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on July 27, 2017